Autologous hematopoietic stem cell transplantation activity for lymphoma and multiple myeloma in China

Little is known regarding the utilization rate of autologous hematopoietic stem cell transplantation (AHSCT) for lymphoma and multiple myeloma (MM) in the mainland of China. In 2019, the autologous stem cell transplantation group of Chinese Society of Clinical Oncology reported 4556 first transplantations with a utilization rate of 3.8% for lymphoma and MM. The AHSCT utilization rates were 2.4% for lymphoma and 11.3% for MM. For lymphoma, the transplantation utilization rate was over 5.0% in the age group of 20–50 years with a peak of 6.5% in the age group of 40–44 years; for MM, the rate was over 10.0% in the age group of 35–65 with a peak of 33.8% in the age group of 45–49 years. The eastern region had higher transplantation utilization rate than central and western regions (4.6% vs. 3.0% vs. 3.3%). There was a wide gap in AHSCT utilization rates between the developed and developing provinces. Beijing had the highest transplantation utilization rate for both lymphoma and MM. This study provided a comprehensive evaluation of AHSCT utilization for lymphoma and MM in China, which will be useful for policy-making with respect to healthcare resource allocation and disease control strategies.